Introduction
============

A positive correlation between low-density lipoprotein cholesterol (LDL-C) levels and the incidence of cardiovascular events has been reported. Specifically, LDL-C-lowering therapy was shown to decrease the incidence of cardiovascular events^[@bib1],\ [@bib2])^. Therefore, target LDL-C levels have been established worldwide to reduce the risk of cardiovascular diseases, including coronary artery disease (CAD), which represents a burden for patients and society.

Target LDL-C levels vary by country. Guidelines outside of Japan recommend an LDL-C level \< 70 mg/dL for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD); however, in Japan, this level is recommended only to patients with a very high-risk profile for secondary prevention. High-risk secondary prevention patients include those with acute coronary syndrome (ACS) and familial hypercholesterolemia and those with diabetes mellitus (DM) complicated with non-cardiogenic cerebral infarction, peripheral artery disease (PAD), chronic kidney disease (CKD), metabolic syndrome, positive smoking status, and more than one major risk factor^[@bib3],\ [@bib4])^. The target LDL-C level in Japanese guidelines is less strict than those in European^[@bib5])^ and American guidelines^[@bib6])^ because there is a lack of evidence for the efficacy of more aggressive lipid-lowering therapy in Japanese patients. Although the target levels in Japan are less strict, many patients cannot achieve these target levels.

Despite a sharp decrease in the incidence of atherosclerotic diseases in general in Japan from the 1960s to the early 2000s, there is evidence of a recent increase in ischemic heart disease owing to westernization of the lifestyle and an increase in the incidence of dyslipidemia^[@bib7]--[@bib14])^. A recent study showed an overall prevalence of ASCVD of 1869 per 100,000 individuals among the employed Japanese population^[@bib10])^ with an event rate (any cardiovascular event) of 4.0% within the first year after diagnosis of ASCVD, representing substantial clinical and economic burdens. Furthermore, DM is not only a notable risk factor for secondary prevention of ASCVD, but also it is on the rise in Japan and throughout Asia^[@bib11])^. Thus, there is a need to determine whether more aggressive lipid-lowering therapy is warranted in Japanese patients with ACS. This article describes the baseline characteristics of patients in the EXPLORE-J study, including comorbidities (DM and hypertension), lipid profile, and cardiovascular risk status, to elucidate the current lipid management status of patients after ACS with a focus on high-risk patients with history of CAD (secondary prevention) and DM.

Methods
=======

Study Design
------------

This is a multicenter, prospective, observational study of Japanese patients presenting with ACS. This article describes the baseline characteristics of those patients, focusing on the lipid profile collected 1) at the first measurement after hospitalization, and 2) at Visit 1 (i.e., at registration \[after informed consent\], which was within 14 days of hospitalization) (**[Supplemental Fig. 1](#F2){ref-type="fig"}**). All other laboratory measurements (including other lipid parameters, glycosylated hemoglobin \[HbA1c\], and fasting blood glucose \[FBG\]) were collected at Visit 1. ACS patients who required hospitalization were consecutively recruited and registered in 59 sites between April 2015 and August 2016 (enrollment period). Participating patients provided written informed consent within 7 days after hospitalization. Next, those who met the inclusion criteria were registered successively to avoid selection bias by the investigator. The study protocol conforms to the ethical guidelines of the 2013 revision of the Declaration of Helsinki and was approved by each institution\'s ethics committee for research involving humans. Additional details of the study methods have been described previously^[@bib12])^.

![Study design\
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Patients
--------

The inclusion criteria were as follows: patients aged ≥ 20 years at the time of informed consent, who developed ACS, including ST elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), or unstable angina (UA). The main exclusion criteria were as follows: patients with chest pain caused by pre-specified significant comorbidities, patients with in-stent thrombosis, patients enrolled in interventional studies that could affect the lipid profile, and those judged as inappropriate for inclusion by the investigators or subinvestigators.

Background Characteristics
--------------------------

Background data (demographic characteristics, physical findings, laboratory data, and medical history) were collected within 14 days of hospitalization (at Visit 1) using electronic case report forms, and have been described previously^[@bib12])^. The presence of a comorbidity was determined at the attending/reporting physician\'s discretion.

Lipid Profile
-------------

The first LDL-C measurement (regardless of the method) after hospitalization was reported. LDL-C levels, both direct and calculated, and other lipid parameters were obtained at Visit 1 (within 14 days after hospitalization for ACS). LDL-C levels were evaluated according to the type of treatment (statin therapy, intensive statin therapy, any lipid-lowering therapy, or no lipid-lowering therapy). Intensive statin therapy was defined as atorvastatin ≥ 20 mg, rosuvastatin ≥ 10 mg, or pitavastatin ≥ 4 mg. The definition of intensive statin therapy in the current study differs from that in the Adult Treatment Panel III of the National Cholesterol Education Program guidelines^[@bib13])^, as lower doses of statins are approved and used in Japan owing to concerns about adverse events.

An additional analysis was conducted in which patients were stratified according to previous history of CAD using the Suita score^[@bib14])^. The Suita score categorizes patients into high-, medium-, and low-risk groups according to patient characteristics (e.g., age, sex, smoking history, blood pressure, high-density lipoprotein cholesterol \[HDL-C\], and LDL-C, among others). The achievement rate of LDL-C target levels for each of the resulting risk groups (\< 100 mg/dL \[secondary prevention\], \< 120 mg/dL \[high risk\], \< 140 mg/dL \[medium risk\], and \< 160 mg/dL \[low-risk\]) was calculated. Because blood pressure was not reported in EXPLORE-J, patients with hypertension were all given a score of 4, which is equivalent to SBP 90--99/DBP 140--159.

Laboratory Parameters in Patients with and without DM
-----------------------------------------------------

Lipid parameters, HbA1c, and FBG were described in patients with and without DM. Serum cholesterol levels were evaluated at each participating study center.

Statistical Analysis
--------------------

Details of the sample size calculations were provided previously^[@bib12])^. Briefly, based on a previous study on Japanese ACS patients (PACIFIC registry)^[@bib15])^ in which the incidence of major adverse cardiovascular events (MACE) was 6.4% at 2 years, the planned sample size was 2000 patients with an estimated precision of approximately 1%, and 95% confidence interval of 5.3%--7.4%.

The background characteristics of the patients were summarized using mean, median, standard deviation (SD), range for continuous data, and number and proportion of patients in each category for categorical data.

Fisher\'s exact test was used for comparison of categorical variables, and *t*-tests, including Welch\'s *t*-test, or the Wilcoxon rank sum test were used for continuous variables as appropriate. A two-sided *p* value of \< 0.05 was considered significant.

Results
=======

The disposition of patients is shown in **[Supplemental Fig. 2](#F3){ref-type="fig"}**. A total of 2016 consecutive ACS patients were registered, 72 of whom were excluded from the analysis for the following reasons: failure to obtain informed consent within 7 days of hospitalization (*n* = 62), unapproved informed consent (*n* = 4), no informed consent obtained (*n* = 2), duplicate entry (*n* = 2), erroneous entry (*n* = 1), and withdrawal because the target number of cases for enrollment was achieved at registration (*n* = 1). Finally, 1944 patients were included in our analysis.

![Patient disposition](jat-26-559-g003){#F3}

Background Characteristics
--------------------------

The mean and SD age of patients overall (*N* = 1944) and those with (*N* = 355) and without history of CAD (*N* = 1589) were 66.0 (12.2) years, 69.4 (11.0) years, and 65.2 (12.3) years, respectively. The mean and SD body mass index of patients overall and those with and without history of CAD were 24.24 (3.59) kg/m^2^, 24.39 (3.64) kg/m^2^, and 24.21 (3.58) kg/m^2^, respectively. Among all patients, 1561/1944 (80.3%) patients were male; among those with and without history of CAD, 301 (84.8%) and 1260 (79.3%) were male (**[Table 1](#T1){ref-type="table"}**). The most common ACS type was STEMI (61.5%), followed by UA (22.6%), and NSTEMI (15.9%). Patients with a history of CAD were more likely to have NSTEMI and UA. The most common lipid-modifying medication used at the time of ACS was statins (overall, 27.3%). Statins were used by 85.0% (531/626) of patients who were taking any lipid-lowering therapies at the time of ACS in this study. Other medications that were commonly used included antihypertensives (51.2%), antiplatelet agents (23.1%), and antiglycemic medications other than insulin (19.7%) (**[Table 2](#T2){ref-type="table"}**).

###### Background characteristics of patients overall and of those with and without a history of CAD

                                                                     *N*    All patients Mean ± SD   History of CAD Mean ± SD   No history of CAD Mean ± SD   *p* value (history of CAD vs no history of CAD)   Statistical test
  ------------------------------------------------------------------ ------ ------------------------ -------------------------- ----------------------------- ------------------------------------------------- ------------------------
  No. of patients                                                           1944                     355                        1589                                                                            
                                                                                                                                                                                                                
  Patient characteristic                                                                                                                                                                                        
      Age (years)                                                    1944   66.0 ± 12.2              69.4 ± 11.0                65.2 ± 12.3                   \< 0.001                                          Welch\'s *t*-test
      Male, *n* (%)                                                  1944   1561 (80.3)              301 (84.8)                 1260 (79.3)                   0.018                                             Fisher\'s exact test
      BMI (kg/m^2^)                                                  1937   24.24 ± 3.59             24.39 ± 3.64               24.21 ± 3.58                  0.391                                             Student\'s *t*-test
      Weight (kg)                                                    1940   65.59 ± 12.90            65.54 ± 12.16              65.61 ± 13.06                 0.929                                             Student\'s *t*-test
      Dyslipidemia, *n* (%)                                          1944   1512 (77.8)              316 (89.0)                 1196 (75.3)                   \< 0.001                                          Fisher\'s exact test
  ACS type                                                           1944                                                                                     \< 0.001                                          Fisher\'s exact test
      STEMI, *n* (%)                                                        1195 (61.5)              153 (43.1)                 1042 (65.6)                                                                     
      NSTEMI, *n* (%)                                                       309 (15.9)               68 (19.2)                  241 (15.2)                                                                      
      UA, *n* (%)                                                           440 (22.6)               134 (37.7)                 306 (19.3)                                                                      
  Creatinine (mg/dL)                                                 1886   1.025 ± 1.143            1.304 ± 1.845              0.963 ± 0.904                 \< 0.001                                          Welch\'s *t*-test
  eGFR (mL/min/1.73 m^2^)^[§](#tf1){ref-type="table-fn"}^, *n* (%)   1886                                                                                     \< 0.001                                          Mann--Whitney *U* test
      \< 15                                                                 39 (2.1)                 16 (4.7)                   23 (1.5)                                                                        
      15 to \< 30                                                           30 (1.6)                 7 (2.0)                    23 (1.5)                                                                        
      30 to \< 60                                                           538 (28.5)               121 (35.2)                 417 (27.0)                                                                      
      60 to \< 90                                                           1034 (54.8)              166 (48.3)                 868 (56.3)                                                                      
      ≥ 90                                                                  245 (13.0)               34 (9.9)                   211 (13.7)                                                                      
  Lipid profile (Visit 1)                                                                                                                                                                                       
      LDL-cholesterol (mg/dL)^[\#](#tf3){ref-type="table-fn"}^       1827   121.2 ± 39.7             103.6 ± 38.0               125.1 ± 39.0                  \< 0.001                                          Student\'s *t*-test
      LDL-cholesterol (mg/dL) (calculated)                           1767   99.4 ± 31.9              90.6 ± 30.5                101.3 ± 31.9                  \< 0.001                                          Student\'s *t*-test
      Total cholesterol (mg/dL)                                      1803   165.2 ± 38.4             156.6 ± 38.6               167.1 ± 38.2                  \< 0.001                                          Student\'s *t*-test
      HDL cholesterol (mg/dL)                                        1831   41.1 ± 11.7              40.9 ± 11.0                41.1 ± 11.8                   0.705                                             Student\'s *t*-test
      Triglycerides (mg/dL)^[†](#tf3){ref-type="table-fn"}^          1838   109.0 (22, 967)          109.0 (36, 552)            109.0 (22, 967)               0.946                                             Wilcoxon rank sum test
      Lipoprotein(a) (mg/dL)^[†](#tf3){ref-type="table-fn"}^         1378   21.20 (0.41, 159.0)      21.00 (0.60, 158.0)        21.25 (0.41, 159.0)           0.666                                             Wilcoxon rank sum test
      Apolipoprotein A1 (mg/dL)                                      1427   108.8 ± 20.8             110.7 ± 19.7               108.3 ± 21.0                  0.103                                             Student\'s *t*-test
      Apolipoprotein B (mg/dL)                                       1425   86.5 ± 22.2              81.0 ± 22.2                87.6 ± 22.1                   \< 0.001                                          Student\'s *t*-test
  Atherosclerotic risk factors (baseline)                                                                                                                                                                       
      Medical history of hypertension (*n*, %)                       1944   1427 (73.4)              301 (84.8)                 1126 (70.9)                   \< 0.001                                          Fisher\'s exact test
      Medical history of diabetes mellitus (*n*, %)                  1944   679 (34.9)               152 (42.8)                 527 (33.2)                    \< 0.001                                          Fisher\'s exact test
      History of smoking (*n*, %)                                    1944                                                                                     \< 0.001                                          Fisher\'s exact test
          Current smoker                                                    739 (38.0)               89 (25.1)                  650 (40.9)                                                                      
          Previous smoker                                                   541 (27.8)               129 (36.3)                 412 (25.9)                                                                      
          None                                                              664 (34.2)               137 (38.6)                 527 (33.2)                                                                      

Estimated glomerular filtration rate \< 60 (CKD stage 3--5).

At first measurement after hospitalization.

Median (min, max).

Conversion factor for creatinine from mg/dL to µmol/L, 88.4.

ACS, acute coronary syndrome; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; NSTEMI, non-ST elevation myocardial infarction; SD, standard deviation; STEMI, ST elevation myocardial infarction; UA, unstable angina.

###### Medications used by patients at the time of acute coronary syndrome in patients overall and in those with and without a history of CAD

                                                                     Total        History of CAD   No history of CAD   *p* value (history of CAD vs no history of CAD)   Statistical test
  ------------------------------------------------------------------ ------------ ---------------- ------------------- ------------------------------------------------- ----------------------
  Previous medication, *N* (%)                                       1944         355              1589                                                                  
                                                                                                                                                                         
  Lipid-modifying medications                                                                                                                                            
      Any lipid-lowering therapies                                   626 (32.2)   232 (65.4)       394 (24.8)          \< 0.001                                          Fisher\'s exact test
      Any statin therapy                                             531 (27.3)   212 (59.7)       319 (20.1)          \< 0.001                                          Fisher\'s exact test
          Intensive statin therapy^[§](#tf4){ref-type="table-fn"}^   31 (5.8)     15 (7.1)         16 (5.0)            0.348                                             Fisher\'s exact test
      Other lipid-lowering therapy (without statin)                  96 (4.9)     20 (5.6)         76 (4.8)            0.496                                             Fisher\'s exact test
      Ezetimibe                                                      40 (2.1)     16 (4.5)         24 (1.5)            0.001                                             Fisher\'s exact test
  Other medications                                                                                                                                                      
      Antihypertensive                                               995 (51.2)   271 (76.3)       724 (45.6)          \< 0.001                                          Fisher\'s exact test
      Antiplatelet                                                   450 (23.1)   267 (75.2)       183 (11.5)          \< 0.001                                          Fisher\'s exact test
      Antiglycemic^[\#](#tf5){ref-type="table-fn"}^                  382 (19.7)   92 (25.9)        290 (18.3)          0.001                                             Fisher\'s exact test
      Antiglycemic (insulin)                                         77 (4.0)     30 (8.5)         47 (3.0)            \< 0.001                                          Fisher\'s exact test
      Oral anticoagulant                                             69 (3.5)     36 (10.1)        33 (2.1)            \< 0.001                                          Fisher\'s exact test
      Anti-arrhythmic                                                54 (2.8)     27 (7.6)         27 (1.7)            \< 0.001                                          Fisher\'s exact test

Intensive statin therapy was defined as atorvastatin ≥ 20 mg, rosuvastatin ≥ 10 mg, or pitavastatin ≥ 4 mg.

Oral agent and injections except insulin.

CAD, coronary artery disease

Lipid Profile
-------------

The mean and SD LDL-C level at first measurement after hospitalization was 121.2 (39.7) mg/dL; 30.3%, 6.6%, and 7.7% of all patients had an LDL-C level \< 100 mg/dL, \< 70 mg/dL, and ≥ 180 mg/dL, respectively. Lipid parameters measured at Visit 1 are shown in **[Table 1](#T1){ref-type="table"}**. Among all patients with available data, 49.6% of 1831 patients had an HDL-C level ≥ 40 mg/dL; 21.9% of 1838 patients had a triglyceride level ≥ 150 mg/dL; and 13.4% of 1378 patients had a lipoprotein(a) level ≥ 50 mg/dL (**[Tables 1](#T1){ref-type="table"}** and **[3](#T3){ref-type="table"}**).

###### Summary statistics of baseline lipid profile in patients overall and in those with and without a history of CAD

  Lipid profile                                              Total         History of CAD   No history of CAD   *p* value   Statistical test
  ---------------------------------------------------------- ------------- ---------------- ------------------- ----------- ------------------------
  LDL-C (mg/dL) at first measurement after hospitalization   1827          332              1495                            
      \< 100                                                 553 (30.3)    173 (52.1)       380 (25.4)          \< 0.001    Fisher\'s exact test
      \< 70                                                  120 (6.6)     50 (15.1)        70 (4.7)            \< 0.001    Fisher\'s exact test
      ≥ 180                                                  141 (7.7)     12 (3.6)         129 (8.6)           0.001       Fisher\'s exact test
  LDL-C (mg/dL) (calculated) at Visit 1                      1767          312              1455                            
      \< 100                                                 998 (56.4)    212 (67.9)       786 (54.0)          \< 0.001    Fisher\'s exact test
      \< 70                                                  254 (14.4)    66 (21.2)        188 (12.9)          \< 0.001    Fisher\'s exact test
      ≥ 180                                                  39 (2.2)      3 (1.0)          36 (2.5)            0.134       Fisher\'s exact test
  HDL-C (mg/dL) at Visit 1                                   1831          327              1504                0.807       Fisher\'s exact test
      \< 40                                                  922 (50.4)    167 (51.1)       755 (50.2)                      
      ≥ 40                                                   909 (49.6)    160 (48.9)       749 (49.8)                      
  Triglycerides (mg/dL) at Visit 1                           1838          327              1511                0.825       Fisher\'s exact test
      \< 150                                                 1435 (78.1)   257 (78.6)       1178 (78.0)                     
      ≥ 150                                                  403 (21.9)    70 (21.4)        333 (22.0)                      
  Lp(a) (mg/dL) at Visit 1                                   1378          240              1138                0.922       Mann--Whitney *U* test
      \< 30                                                  919 (66.7)    162 (67.5)       757 (66.5)                      
      30 to \< 50                                            275 (20.0)    43 (17.9)        232 (20.4)                      
      ≥ 50                                                   184 (13.4)    35 (14.6)        149 (13.1)                      

CAD, coronary artery disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a)

**[Table 4](#T4){ref-type="table"}** shows the relationship between history of CAD and LDL-C levels at first measurement after hospitalization. Patients with a previous history of CAD had lower mean LDL-C levels, were notably more likely to have LDL-C levels \< 100 mg/dL (52.1% vs 25.4%), and were more likely to be on statin therapy (59.7% vs 20.1%) than those without a previous history of CAD (**[Table 2](#T2){ref-type="table"}**).

###### Relationship between history of CAD and LDL-C level at first measurement after hospitalization among patients overall and according to lipid-lowering therapy

                                                             History of CAD[§](#tf6){ref-type="table-fn"}   No history of CAD[§](#tf6){ref-type="table-fn"}   Statistical tests[\#](#tf7){ref-type="table-fn"} (patients with/without CAD), *p* values                                                                        
  ---------------------------------------------------------- ---------------------------------------------- ------------------------------------------------- ------------------------------------------------------------------------------------------ ----------- ------ -------------- ------------ ---------- ---------- ----------
  All patients at hospitalization                            332                                            103.6 ± 38.0                                      173 (52.1)                                                                                 50 (15.1)   1495   125.1 ± 39.0   380 (25.4)   70 (4.7)   \< 0.001   \< 0.001
  No lipid-lowering therapy                                  116                                            120.6 ± 40.5                                      37 (31.9)                                                                                  11 (9.5)    1131   130.1 ± 39.6   234 (20.7)   41 (3.6)   0.014      0.009
  Any lipid-lowering therapy                                 216                                            94.5 ± 33.3                                       136 (63.0)                                                                                 39 (18.1)   364    109.6 ± 32.9   146 (40.1)   29 (8.0)   \< 0.001   \< 0.001
  Any statin therapy                                         196                                            93.1 ± 33.2                                       128 (65.3)                                                                                 39 (19.9)   294    107.5 ± 31.3   125 (42.5)   25 (8.5)   \< 0.001   \< 0.001
  Intensive statin therapy^[†](#tf8){ref-type="table-fn"}^   12                                             96.2 ± 35.2                                       7 (58.3)                                                                                   2 (16.7)    16     112.9 ± 34.1   5 (31.3)     0 (0.0)    \-         \-
  Fibrate therapy                                            5                                              93.0 ± 16.5                                       2 (40.0)                                                                                   0 (0.0)     27     118.9 ± 29.1   5 (18.5)     2 (7.4)    \-         \-
  Ezetimibe therapy                                          14                                             105.9 ± 44.2                                      6 (42.9)                                                                                   3 (21.4)    22     109.0 ± 47.2   9 (40.9)     6 (27.3)   \-         \-
  EPA/DHA therapy                                            23                                             83.3 ± 31.9                                       16 (69.6)                                                                                  6 (26.1)    41     108.0 ± 31.6   18 (43.9)    4 (9.8)    \-         \-
  Other lipid-lowering therapy (no PCSK9i)                   20                                             100.2 ± 32.1                                      11 (55.0)                                                                                  2 (10.0)    29     110.5 ± 49.5   14 (48.3)    4 (13.8)   \-         \-

Patients with available LDL-C level at the time of ACS diagnosis.

Statistical comparisons were carried out only for *n* ≥ 100.

Intensive statin therapy was defined as atorvastatin ≥ 20 mg, rosuvastatin ≥ 10 mg, or pitavastatin ≥ 4 mg.

Conversion factor for LDL-C from mg/dL to mmol/L, 0.0259.

ACS, acute coronary syndrome; CAD, coronary artery disease; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LDL-C, low-density lipoprotein cholesterol; PCSK9i, proprotein convertase subtilisin/kexin 9 inhibitor; SD, standard deviation

In the additional analysis using the Suita score, 355 (18.3%) of 1944 patients with a history of CAD were categorized as the secondary prevention group and 1589 patients without history of CAD were categorized as the primary prevention group. The latter were further categorized as high-risk (*n* = 1368 \[86.1%\]), medium-risk (190 \[12.0%\]), and low-risk (31 \[2.0%\]) groups. In the secondary prevention group, 173 (52.1%) patients achieved LDL-C target \< 100 mg/dL. In the primary prevention high-risk group, 578 (45.8%) achieved LDL-C target \< 120 mg/dL. The majority of primary prevention patients were categorized as high-risk.

Comorbidities and cardiovascular risk factors for patients overall are summarized in **[Supplemental Fig. 3](#F4){ref-type="fig"}**.

![Comorbidities and cardiovascular risk factors for patients overall\
CAD, coronary artery disease; CVA, cerebrovascular accident; DM, diabetes mellitus; PAD, peripheral artery disease](jat-26-559-g004){#F4}

Laboratory Parameters in Patients with and without DM
-----------------------------------------------------

The distribution of LDL-C levels at first measurement after hospitalization among patients with and without DM according to their previous history of CAD (positive or negative) is shown in **[Fig. 1](#F1){ref-type="fig"}**. In general, the proportions of patients with an LDL-C level \< 100 mg/dL and \< 70 mg/dL were higher among those with DM vs those without DM, regardless of their previous history of CAD. The difference was especially notable among patients with a previous history of CAD with an LDL-C level \< 100 mg/dL (with vs without DM: 57.2% vs 48.1%) and \< 70 mg/dL (with vs without DM: 19.3% vs 11.8%).

![Distribution of LDL-C levels at first measurement after hospitalization among patients with and without DM without history of CAD (A) and in those with history of CAD (B)\
Conversion factor for LDL-C from mg/dL to mmol/L: 0.0259\
CAD, coronary artery disease; DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation](jat-26-559-g001){#F1}

A comparison of the results of lipid profile after stabilization (i.e., Visit 1) among patients with and without DM is shown in **[Supplemental Table 1](#T5){ref-type="table"}**. The levels of most lipid parameters were significantly higher among patients without DM than those with DM, except for triglyceride level, which was significantly higher in those with DM (**[Supplemental Fig. 4](#F5){ref-type="fig"}**).

###### Lipid profile after stabilization (i.e., Visit 1) in patients with and without DM

                          DM                                                   No DM                                                 *p* value
  ----------------------- ---------------------------------------------------- ----------------------------------------------------- ------------------------------------------
  LDL-C (calc), mg/dL     94.2 (29.6)                                          102.3 (32.8)                                          \< 0.001^[§](#tf9){ref-type="table-fn"}^
  LDL-C (direct), mg/dL   96.6 (30.4)                                          104.4 (33.5)                                          \< 0.001^[§](#tf9){ref-type="table-fn"}^
  TC, mg/dL               159.2 (36.4)                                         168.4 (39.1)                                          \< 0.001^[§](#tf9){ref-type="table-fn"}^
  HDL-C                   39.1 (10.5)                                          42.2 (12.1)                                           \< 0.001^[§](#tf9){ref-type="table-fn"}^
  TG                      113.0 (26, 665)^[‡](#tf12){ref-type="table-fn"}^     107.0 (22, 967)^[‡](#tf12){ref-type="table-fn"}^      0.001^[\#](#tf10){ref-type="table-fn"}^
  Apolipoprotein A1       106.5 (19.3)                                         110.0 (21.4)                                          0.002^[§](#tf9){ref-type="table-fn"}^
  Apolipoprotein B        84.9 (22.1)                                          87.4 (22.3)                                           0.041^[†](#tf11){ref-type="table-fn"}^
  Lipoprotein(a)          20.0 (1.0, 148.0)^[‡](#tf12){ref-type="table-fn"}^   23.0 (0.41, 159.0)^[‡](#tf12){ref-type="table-fn"}^   0.003^[\#](#tf10){ref-type="table-fn"}^

Data are presented as mean (standard deviation).

Welch\'s *t*-test;

Wilcoxon rank sum test;

Student\'s *t*-test;

median (Min, Max).

Conversion factors for LDL-C, TC, and HDL-C from mg/dL to mmol/L, 0.0259; TG from mg/dL to mmol/L, 0.0113; apolipoprotein A1 and B from mg/dL to g/L, 0.01; and lipoprotein(a) from mg/dL to µmol/L, 0.0357.

DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides

![Distribution of HDL-C (A) and triglycerides (B) at Visit 1 in patients with and without DM\
Conversion factors for HDL-C from mg/dL to mmol/L, 0.0259; and TG from mg/dL to mmol/L, 0.0113.\
DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; SD, standard deviation; TG, triglycerides](jat-26-559-g005){#F5}

The status of glycemic control in DM patients in terms of HbA1c and FBG is shown in **[Supplemental Fig. 5](#F6){ref-type="fig"}**. The mean and SD HbA1c and FBG were 7.38% (1.43%) and 144.8 (46.2) mg/dL, respectively, among patients with DM. Furthermore, 51.3% and 61.3% of patients with DM had an HbA1c ≥ 7.0% and FBG ≥ 125 mg/dL, respectively.

![Glucose control at Visit 1 in patients with and without DM in terms of HbA1c (A) and FBG (B)\
Conversion factor for FBG from mg/dL to mmol/L, 0.0555.\
DM, diabetes mellitus; FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin; SD, standard deviation](jat-26-559-g006){#F6}

Discussion
==========

The EXPLORE-J study is one of the largest ACS registries in Japan to explore the current lipid management status of ACS patients. Among the 1944 patients included in the present study, most had a history of dyslipidemia (77.8%). Among all patients in the present study and among those with a previous history of CAD, respectively, 30.3% and 52.1% had LDL-C \< 100 mg/dL and 6.6% and 15.1% had LDL-C \< 70 mg/dL at the first measurement after hospitalization. These findings suggest that a large proportion of patients were not meeting the recommended LDL-C target level of \< 100 mg/dL for secondary prevention of CAD, and even those who had achieved target LDL-C levels still developed ACS. A reason for this may be the low rate of lipid-lowering therapy use (any statin) in the present study (27.3%). It is possible that patients are not receiving adequate doses of statins, and alternative lipid-lowering agents may be warranted in some patients; therefore, untreated patients may be more susceptible to cardiovascular events. For many patients, the current target LDL-C level for secondary prevention in Japan may be suboptimal, especially among patients with a previous history of CAD.

Regarding other lipid parameters, no notable differences were shown in the distribution of all patients according to HDL-C level (approximately 50% of the patients had HDL-C level \< 40 and ≥ 40 mg/dL at Visit 1). Triglyceride levels were within the target level (\< 150 mg/dL) in 78.1% of the patients.

According to the Suita score analysis, those categorized as having high risk accounted for the majority of patients (84% of the primary prevention subset) in the study population hospitalized for ACS, implying the reliability of the score as a tool to predict the likelihood of developing CAD in the future. Additionally, these findings strongly suggest that the multidisciplinary approach is important for the prevention of CAD. The low target LDL-C achievement rate in the secondary prevention/high-risk groups may suggest that more stringent LDL-C control is required. Further study to adopt the Suita score for targeting LDL-C level seems to be warranted.

In the present study, patients without a previous history of CAD had a higher mean LDL-C level than those with a previous history of CAD. These findings are consistent with those of a previous study in which the mean LDL-C levels among patients with a previous history of CAD were generally lower than those among patients without a previous history of CAD^[@bib16])^. In both studies, the mean LDL-C levels were lower in patients with DM vs those without DM, regardless of their previous history of CAD. The reason patients with DM tend to have lower LDL-C levels in general may be owing to higher use of statins and other lipid-lowering therapies. Patients being treated for DM may also see physicians more often and be adhering to diet and exercise therapies, which would contribute to a more favorable lipid profile in general. This is evidenced by the Nationwide Lifestyle Intervention Program Targeting Metabolic Syndrome, which has shown that regular health checkups and guidance on lifestyle modifications had some success in Japan in preventing metabolic syndrome and its sequelae^[@bib17],\ [@bib18])^.

While DM patients may be more aggressively treated by clinicians, these patients may still experience ACS events at lower LDL-C levels. This suggests that the target LDL-C level may require re-evaluation in Japan. Moreover, the idea of implementing a lower target LDL-C level in DM patients to reduce cardiovascular risk is supported by a previous study by Howard et al., which compared the effect of implementing aggressive vs standard LDL-C target levels (\< 70 vs \< 100 mg/dL) for DM patients with atherosclerosis. Howard et al. found that more aggressive LDL-C target levels provided greater benefits in terms of reducing the progression of atherosclerosis compared with standard LDL-C target levels^[@bib19])^.

The present study has some limitations, including those inherent to the observational study design and small sample size. Serum LDL-C levels can decrease early after the development of ACS^[@bib20])^; however, we did not assess the specific timing of LDL-C measurement. This timing could have varied among the cohorts. Not all of the study patients had a complete lipid profile at hospitalization.

Conclusions
===========

High-risk patients presenting with ACS may require more aggressive treatment with intensive statin therapy, ezetimibe, or proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors. Further analyses are warranted as to whether more aggressive LDL-C target levels are needed in high-risk patients, along with further investigation of risk factors associated with the onset of ACS.

Upcoming data on MACE from the 2-year observation period will be evaluated to further identify high-risk patients, and will provide insight into current post-ACS cardiovascular risk factor management, familial hypercholesterolemia diagnosis, Achilles tendon thickness, and PCSK9 levels in ACS patients.
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ACS

:   acute coronary syndrome

ASCVD

:   atherosclerotic cardiovascular disease

BMI

:   body mass index

CAD

:   coronary artery disease

CKD

:   chronic kidney disease

DM

:   diabetes mellitus

FBG

:   fasting blood glucose

HbA1c

:   glycosylated hemoglobin

HDL-C

:   high-density lipoprotein cholesterol

LDL-C

:   low-density lipoprotein cholesterol

MACE

:   major adverse cardiovascular events

NSTEMI

:   non-ST elevation myocardial infarction

PAD

:   peripheral artery disease

PCSK9

:   proprotein convertase subtilisin/kexin 9

SD

:   standard deviation

STEMI

:   ST elevation myocardial infarction

UA

:   unstable angina
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